FGF2 and cardiomyopathy: Decreased tumor growth (synergistic and non-synergistic)Increased survival (synergistic)Decreased off-target toxicity (e.g., decreased: leukocyte loss, reticulocytosis, weight loss, ascites accumulation, hepatotoxicity, cardiomyopathy, renal toxicity, lipid oxidation)Decreased protein levels synergistically (e.g., VEGF, bFGF, mTOR)